New advances in blockade of the renin angiotensin system- The role of renin blockade

Sandra MacRury; L F Clark; G F Rushworth; Stephen J Leslie

doi:10.2174/157340210793611677

New advances in blockade of the renin angiotensin system- The role of renin blockade

Sandra MacRury
, L F Clark
, G F Rushworth
, Stephen J Leslie

Resultado de pesquisa › revisão de pares

Resumo

Direct Renin Inhibitors (DRIs) are a new class of medication, and are the first which block the rate-limiting step of the renin-angiotensin-aldosterone-system (RAAS). Aliskiren, the first licensed orally active DRI, has been shown to be an effective antihypertensive agent. This review article outlines the pharmacological basis for DRI therapy, from discovery of the class to ongoing clinical trials and novel therapeutic applications of aliskiren.

Idioma original	English
Páginas (de-até)	222
Número de páginas	231
Revista	Current Hypertension Reviews
Volume	6
Número de emissão	4
DOIs	https://doi.org/10.2174/157340210793611677
Estado da publicação	Published - 2014

ODS da ONU

Este resultado contribui para o(s) seguinte(s) Objetivo(s) de Desenvolvimento Sustentável

Acesso ao documento

10.2174/157340210793611677

http://benthamscience.com/journal/abstracts.php?journalID=chr&articleID=72883

Citar isto

@article{913fb85bdabc42d3ad1740b61b8d1ba2,

title = "New advances in blockade of the renin angiotensin system- The role of renin blockade",

abstract = "Direct Renin Inhibitors (DRIs) are a new class of medication, and are the first which block the rate-limiting step of the renin-angiotensin-aldosterone-system (RAAS). Aliskiren, the first licensed orally active DRI, has been shown to be an effective antihypertensive agent. This review article outlines the pharmacological basis for DRI therapy, from discovery of the class to ongoing clinical trials and novel therapeutic applications of aliskiren. ",

author = "Sandra MacRury and Clark, \{L F\} and Rushworth, \{G F\} and Leslie, \{Stephen J\}",

year = "2014",

doi = "10.2174/157340210793611677",

language = "English",

volume = "6",

pages = "222",

journal = "Current Hypertension Reviews",

issn = "1875-6506",

publisher = "Bentham Science Publishers B.V.",

number = "4",

}

TY - JOUR

T1 - New advances in blockade of the renin angiotensin system- The role of renin blockade

AU - MacRury, Sandra

AU - Clark, L F

AU - Rushworth, G F

AU - Leslie, Stephen J

PY - 2014

Y1 - 2014

N2 - Direct Renin Inhibitors (DRIs) are a new class of medication, and are the first which block the rate-limiting step of the renin-angiotensin-aldosterone-system (RAAS). Aliskiren, the first licensed orally active DRI, has been shown to be an effective antihypertensive agent. This review article outlines the pharmacological basis for DRI therapy, from discovery of the class to ongoing clinical trials and novel therapeutic applications of aliskiren.

AB - Direct Renin Inhibitors (DRIs) are a new class of medication, and are the first which block the rate-limiting step of the renin-angiotensin-aldosterone-system (RAAS). Aliskiren, the first licensed orally active DRI, has been shown to be an effective antihypertensive agent. This review article outlines the pharmacological basis for DRI therapy, from discovery of the class to ongoing clinical trials and novel therapeutic applications of aliskiren.

U2 - 10.2174/157340210793611677

DO - 10.2174/157340210793611677

M3 - Article

SN - 1875-6506

VL - 6

SP - 222

JO - Current Hypertension Reviews

JF - Current Hypertension Reviews

IS - 4

ER -

New advances in blockade of the renin angiotensin system- The role of renin blockade

Resumo

ODS da ONU

Acesso ao documento

Impressão digital

Citar isto